PAUL HOPPER ON WHETHER HIS NEW VENTURE RADIOPHARM THERANOSTICS WILL BE A TAKEOVER TARGET, AND THE KEYS TO BIOTECH SUCCESS

© Stockhead Australia Imugene executive chairman Paul Hopper Paul Hopper, the man behind Viralytics, Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM), is about to launch another biotech venture  – Radiopharm Theranostics – onto the ASX later this week. Radiopharm Theranostics is pencilled in for a listing at 11am on Thursday just a few months after its pre-IPO funding r...

Source: